Kartik Anand1, Thuy L Phung2, Eric H Bernicker3, Philip T Cagle2, Randall J Olsen2, Jessica S Thomas4. 1. Cancer Center, Houston Methodist Hospital, Houston, TX. 2. Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medicine, Houston, TX. 3. Cancer Center, Houston Methodist Hospital, Houston, TX. Electronic address: bernicker@houstonmethodist.org. 4. Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medicine, Houston, TX. Electronic address: jsthomas@houstonmethodist.org.
Abstract
INTRODUCTION: In order to standardize and expedite molecular biomarker testing, we implemented reflex ordered testing of targeted gene alterations in newly diagnosed lung adenocarcinomas within our hospital system. PATIENTS AND METHODS: Reflex ordered testing of specific molecular biomarkers at the time of pathologic diagnosis of lung adenocarcinoma was approved and adopted system-wide in our hospital during 2017. Through institutional review board approval, we retrospectively looked at cohort of patients whose specimens received a diagnosis of lung adenocarcinoma, with molecular biomarker testing performed at Houston Methodist Hospital between 2016 and 2018. We compared average turnaround time (TAT) from 2016 (prior to reflex ordered testing) to 2017 and 2018 (post reflex ordered testing). RESULTS: Standard molecular testing performed on 39 patients in 2016 had an average TAT of 52.6 days, whereas reflex ordered molecular testing in 2017 yielded an average TAT of 26.5 days (n = 127) and 15.6 days in 2018 (n = 54). The average TAT for reporting of molecular results significantly decreased by 37 days (P = .0002) within our hospital system post adoption of reflex ordered testing for lung adenocarcinoma. Reflex ordered testing also resulted in a higher variant detection rate than standard molecular biomarker ordering practices (48.8% vs. 25.6%; P < .05). Overall, the frequencies and types of variants identified among our cohort were similar to previous reports. CONCLUSIONS: Reflex ordered testing of molecular biomarkers in lung adenocarcinoma led to significantly decreased TAT within our hospital system and higher detection rates of targeted gene alterations.
INTRODUCTION: In order to standardize and expedite molecular biomarker testing, we implemented reflex ordered testing of targeted gene alterations in newly diagnosed lung adenocarcinomas within our hospital system. PATIENTS AND METHODS: Reflex ordered testing of specific molecular biomarkers at the time of pathologic diagnosis of lung adenocarcinoma was approved and adopted system-wide in our hospital during 2017. Through institutional review board approval, we retrospectively looked at cohort of patients whose specimens received a diagnosis of lung adenocarcinoma, with molecular biomarker testing performed at Houston Methodist Hospital between 2016 and 2018. We compared average turnaround time (TAT) from 2016 (prior to reflex ordered testing) to 2017 and 2018 (post reflex ordered testing). RESULTS: Standard molecular testing performed on 39 patients in 2016 had an average TAT of 52.6 days, whereas reflex ordered molecular testing in 2017 yielded an average TAT of 26.5 days (n = 127) and 15.6 days in 2018 (n = 54). The average TAT for reporting of molecular results significantly decreased by 37 days (P = .0002) within our hospital system post adoption of reflex ordered testing for lung adenocarcinoma. Reflex ordered testing also resulted in a higher variant detection rate than standard molecular biomarker ordering practices (48.8% vs. 25.6%; P < .05). Overall, the frequencies and types of variants identified among our cohort were similar to previous reports. CONCLUSIONS: Reflex ordered testing of molecular biomarkers in lung adenocarcinoma led to significantly decreased TAT within our hospital system and higher detection rates of targeted gene alterations.
Authors: Martin Zacharias; Gudrun Absenger; Karl Kashofer; Robert Wurm; Jörg Lindenmann; Angelika Terbuch; Selma Konjic; Stefan Sauer; Franz Gollowitsch; Gregor Gorkiewicz; Luka Brcic Journal: Transl Lung Cancer Res Date: 2021-11
Authors: Ethan A Burns; Joe E Ensor; Jim Hsu; Jessica S Thomas; Randall J Olsen; Eric H Bernicker Journal: J Thorac Dis Date: 2021-08 Impact factor: 2.895
Authors: Sarah Zhou; Daniel Sikorski; Honghao Xu; Andrei Zubarev; May Chergui; François Lagacé; Wilson H Miller; Margaret Redpath; Stephanie Ghazal; Marcus O Butler; Teresa M Petrella; Joël Claveau; Carolyn Nessim; Thomas G Salopek; Robert Gniadecki; Ivan V Litvinov Journal: Cancers (Basel) Date: 2021-05-10 Impact factor: 6.639
Authors: Brandon S Sheffield; Andrea Beharry; Joanne Diep; Kirstin Perdrizet; Marco A J Iafolla; William Raskin; Shaan Dudani; Mary Anne Brett; Blerta Starova; Brian Olsen; Parneet K Cheema Journal: Curr Oncol Date: 2022-02-23 Impact factor: 3.677